Policaptil Gel Retard Intake Reduces Postprandial Triglycerides, Ghrelin and Appetite in Obese Children: A Clinical Trial

What Was Tested

Researchers studied Ghrelin in this randomized controlled trial publication.

The aim of this study is to test the hypothesis that the intake of Policaptil Gel Retard® (PGR) is able to affect appetite, metabolic and hormonal postprandial profile in obese children. 46 obese children were randomly assigned to treatment with PGR or placebo, in a double blind clinical trial.

Why It Was Studied

Blood samples were taken at baseline and for 4 hours, for measuring blood lipids, glucose, insulin, ghrelin, and glucagon like peptide-1 (GLP-1).

Appetite was quantified using a visual analog scale.

Who Took Part

The study group was 46 children.

By PubMed's age tags, the people studied were children, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The children were allocated by chance, so the Ghrelin group and the comparison group should start out alike.

Neither the children nor the staff measuring them knew who was on Ghrelin, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Ghrelin could be set against what happens without it.

What Was Measured

Blood samples were taken at baseline and for 4 hours, for measuring blood lipids, glucose, insulin, ghrelin, and glucagon like peptide-1 (GLP-1).

Topics PubMed links to this paper include Appetite, Blood Glucose, Eating, Gels, Ghrelin, Insulin and Macromolecular Substances.

Author keywords: children, fibers, obesity, postprandial phase and triglycerides.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Ghrelin in 46 children.

The publication is from 2020 (Nutrients), a journal based in Switzerland.

More context: the Ghrelin compound page, all human trials.